PP
AXSM icon

Paloma Partners’s Axsome Therapeutics AXSM Stock Holding History

Paloma Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,599
Closed -$311K – 1092
2021
Q2 		$311K Buy
+4,599
New +$276K 0.01% 1289
2020
Q3 		– Sell
-17,587
Closed -$1.45M – 2080
2020
Q2 		$1.45M Buy
+17,587
New +$1.35M 0.03% 759
2017
Q3 		– Sell
-48,900
Closed -$269K – 2091
2017
Q2 		$269K Buy
+48,900
New +$205K ﹤0.01% 1849

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Paloma Partners's AXSM Position: Q3 2021 in Review

Paloma Partners sold out of Axsome Therapeutics (AXSM) in Q3 2021, closing a stake of 4,599 shares — an estimated $311K sold.

Paloma Partners first reported a position in AXSM in Q2 2017 and held it in 3 quarters. The position peaked at $1.45M in Q2 2020. 171 funds tracked by Wall St. Rank hold AXSM as of Q3 2021.

  • Paloma Partners reported no remaining Axsome Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Paloma Partners sold 4,599 Axsome Therapeutics shares in Q3 2021, an estimated $311K.
  • Paloma Partners first reported a position in Axsome Therapeutics in Q2 2017 and held it in 3 quarters.
  • Paloma Partners's Axsome Therapeutics position peaked at $1.45M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2021.

Based on Paloma Partners's 13F filing for Q3 2021, filed 15 Nov 2021.